
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio Inc. has demonstrated a positive outlook based on its strategic management decisions and the recent litigation settlement, which has significantly increased royalty rates on Jemperli sales from 4-8% to 8-25% and added a $60 million one-time payment. The settlement with GSK not only suggests increased financial commitments but also reflects management's confidence in the company's stability, despite associated litigation risks. Furthermore, with the potential for additional indications and assets in development, the company is positioned to leverage its robust clinical pipeline, supporting operational needs and enhancing shareholder returns.
Bears say
AnaptysBio Inc faces significant financial risks due to potential safety concerns and lower-than-expected efficacy from its clinical programs, specifically regarding its lead candidates, rosnilimab and ANB032. Additionally, the company could encounter intensified commercial competition and regulatory challenges, which may hinder its ability to achieve anticipated revenue levels, particularly in light of existing market treatments. Legal uncertainties surrounding Jemperli, including unfavorable resolutions that could impact revenue, further amplify the negative outlook for AnaptysBio's stock performance.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares